A viable, improved method is to use Flt3L to increase the number of cDCs, which has shown potential in reversing the tumor matrix changes and tumor progression caused by neoantigens in early-stage PDAC; however, in advanced PDAC, the use of Flt3L alone is insufficient and needs to be combined with a CD40 antibody and radiotherapy to enhance cDC function and fully release neoantigens via a tri-therapy approach, but this method is feasible only in mice and lacks further research [78]. This evidence concerns the gene FLT3LG and neoplasm.